RxDoctor Payments Data

Colleen Darnell, MD

Hematology & Oncology · Edgewood, KYNPI 1033374046

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 30.8% of the total. 2025 is the largest year on record at $3,574, more than ten times the $171 reported in 2019.

$6,589in general payments, 2019–2025

Across 37 payments — averaging $178.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Merck$2K
  • Johnson & Johnson$1K
  • AstraZeneca$416
  • Jazz Pharmaceuticals Inc.$391
  • Tempus AI, Inc$326
  • plus $451 from 7 others
$344,448in research payments, 2019–2025

Across 29 payments — averaging $11,878 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$136K
  • E.r. Squibb & Sons, L.L.C.$124K
  • GSK$46K
  • Novocure GmbH$38K

What the payments were for

  • Consulting fees$2,88044%
  • Travel & lodging$1,53723%
  • Food & beverage$2,00530%
  • Education$1663%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,589 in reported general payments places this provider in the 60th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$121,043
Medicare patients
335
Services billed
1,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate16$684,174
TagrissoOsimertinib Mesylate40$674,615
RevlimidLenalidomide27$624,530
Lenalidomide30$496,959
PomalystPomalidomide13$305,957
ImbruvicaIbrutinib26$278,693
BrukinsaZanubrutinib14$211,886
IbrancePalbociclib12$194,474
SorafenibSorafenib Tosylate12$80,480
EliquisApixaban68$60,492
XtandiEnzalutamide12$58,905
Abiraterone Acetate24$52,315
XareltoRivaroxaban15$21,282
CreonLipase/Protease/Amylase13$16,828
Ondansetron Hcl27$9,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$416$674,61540 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$2,030$305,95713 claims
PfizerIbrance, Eliquis$14$254,96680 claims
Johnson & JohnsonXarelto$1,080$21,28215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Edgewood

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →